Systemic lupus erythematosus is a chronic autoimmune condition characterized by immunological dysregulation, leading to the production of autoantibodies and subsequent organ dysfunction. The CD154/CD40 signaling pathway is crucial to the pathophysiology of systemic lupus erythematosu, since it facilitates T cell-dependent B cell activation, resulting in the generation of autoreactive B cells and the production of detrimental autoantibodies. Recent breakthroughs in nanotechnology have generated novel options for modulating immune responses in systemic lupus erythematosus, offering potential therapeutic strategies for accurately targeting specific immunological pathways while reducing adverse effects. Nanoparticles (NPs) have emerged as potent instruments in SLE therapy due to their capacity to target immune cells, encapsulate pharmaceuticals, and alter immunological signaling. This review analyzes the utilization of nanoparticles to modulate immune responses in systemic lupus erythematosus, with a particular focus on the CD154/CD40 pathway. We analyze various methodologies, including targeted drug delivery, immune cell modulation, and the induction of immunological tolerance, highlighting key research that has demonstrated the effectiveness of nanoparticles in reducing autoimmune responses and mitigating disease symptoms. Despite promising results in preclinical models, challenges such as biocompatibility, immunogenicity, and scalability remain. The progression of nanoparticle-based therapeutics presents a promising future for enhanced, targeted, and personalized treatments for systemic lupus erythematosus.